| Literature DB >> 29085575 |
Arezoo Fallah1,2, Mohammad Ahangarzadeh Rezaee1,3, Alka Hasani3, Mohammad Hossein Soroush Barhaghi4, Hossein Samadi Kafil5.
Abstract
OBJECTIVES: Acinetobacter baumannii has a high propensity to form biofilm and frequently causes medical device-related infections with multiple-drug-resistance in hospitals. The aim of this work is to study antimicrobial resistance and the role of bap and cpaA genes in biofilm formation by A. baumannii to understand how this pathogen persists in the hospital environment.Entities:
Keywords: Acinetobacter baumannii; Antibiotic resistance; Bap; Biofilm; CpaA
Year: 2017 PMID: 29085575 PMCID: PMC5651469 DOI: 10.22038/IJBMS.2017.9105
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Figure 1Antibiotic susceptibility of the Acinetobacter baumannii isolates
Abbreviations; MRP, meropenem; AN, amikacin; IMP, imipenem; CL, colistin; CAZ, ceftazidime; GEN, gentamicin; SXT, cotrimoxazole; CP, ciprofloxacin; CTX, cefotaxime; TE, tetracycline; CPM, cefepime. Numbers depicted in the above figure present susceptibility as percentage of bacterial isolates. Mueller-Hinton agar was used for susceptibility test. The inoculum concentration was 1.5 × 108
Antibiotic resistance patterns of Acinetobacter baumannii isolates according to various specimens
| Specimen | CP | IMP | MRP | GEN | SXT | AN | CAZ | CTX | CPM | TE | CL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tracheal aspirates | 45 | 46 | 23 | 22 | 39 | 26 | 48 | 49 | 49 | 23 | 3 |
| Urine | 12 | 11 | 5 | 5 | 10 | 8 | 13 | 13 | 14 | 6 | 0 |
| Wound | 14 | 13 | 10 | 8 | 10 | 8 | 14 | 14 | 14 | 7 | 0 |
| Blood | 10 | 12 | 8 | 7 | 8 | 9 | 12 | 11 | 12 | 7 | 1 |
| Bronchial secretion | 4 | 4 | 2 | 3 | 2 | 3 | 4 | 4 | 4 | 1 | 0 |
| Pharynx | 5 | 5 | 3 | 5 | 4 | 5 | 5 | 5 | 5 | 3 | 0 |
| Bile | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 91 | 92 | 52 | 51 | 74 | 60 | 97 | 97 | 99 | 47 | 4 |
MRP: meropenem; AN: amikacin; IMP, imipenem; CL, colistin; CAZ, ceftazidime; GEN, gentamicin; SXT, cotrimoxazole; CP, ciprofloxacin; CTX, cefotaxime; TE, tetracycline; CPM, cefepime
The percentage of virulence genes detected in Acinetobacter baumannii strains according to the site of isolation
| Genes | Tracheal aspirates | Urine | Wound | Blood | Bronchial secretion | Pharynx | Bile | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Positive | 45 | 12 | 13 | 11 | 5 | 5 | 1 | 92 | |
| Negative | 5 | 1 | 1 | 1 | 0 | 0 | 0 | 8 | |
| Positive | 16 | 5 | 3 | 6 | 5 | 1 | 0 | 36 | |
| Negative | 34 | 8 | 11 | 6 | 0 | 4 | 1 | 64 | |
| Total | 50 | 13 | 14 | 12 | 5 | 5 | 1 | 100 | |
Statistical analysis of the relationship between biofilm formation and the presence of bap and cpaA genes in Acinetobacter baumannii strains with multidrug resistance (MDR)
| MDR | ||||||||
|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | Total | ||
| Biofilm | Weak | 19 (76.0%) | 6 (24.0%) | 4 (16.0%) | 21 (84.0%) | 16 (64.0%) | 9 (36.0%) | 25 |
| Moderate | 32 (100%) | 0 (0%) | 12 (37.5%) | 20 (62.5%) | 31 (96.9%) | 1 (3.1%) | 32 | |
| Strong | 41 (95.5%) | 2 (4.0%) | 20 (46.5%) | 23 (53.5%) | 41 (95.3%) | 2 (4.7%) | 43 | |
| Total | 92 (92.0%) | 12 (12.0%) | 36 (36.0%) | 64 (64.0%) | 88 (88.0%) | 12 (12.0%) | 100 | |
| 0.003 | 0.40 | 0.000 | ||||||